KYTX250117P2500
- 0.00
- 0.000.00%
Kyverna Therapeutics Newsroom
Express News | Kyverna Therapeutics Strengthens Leadership Team to Accelerate Next Phase of Growth
Press Release: Kyverna Therapeutics Strengthens Leadership Team to Accelerate Next Phase of Growth
We Think Kyverna Therapeutics (NASDAQ:KYTX) Can Afford To Drive Business Growth
Kyverna Therapeutics Analyst Ratings
H.C. Wainwright Maintains Kyverna Therapeutics(KYTX.US) With Hold Rating, Cuts Target Price to $6
Institutional Investors of Kyverna Therapeutics, Inc. (NASDAQ:KYTX) Must Be Disappointed After Last Week's 18% Drop
Kyverna Therapeutics Is Maintained at Overweight by Wells Fargo
Wells Fargo Maintains Kyverna Therapeutics(KYTX.US) With Buy Rating, Cuts Target Price to $24
Express News | Kyverna Therapeutics, Inc. : Wells Fargo Cuts Target Price to $24 From $44
Express News | Kyverna Therapeutics Inc - Kyv-101 Demonstrates Robust Safety and Tolerability
Express News | Kyverna Therapeutics Announces New Patient Data Highlighting Potential of Kyv-101 for Treatment of Lupus Nephritis in Symposium at Acr Convergence 2024
Kyverna Therapeutics Announces New Patient Data Highlighting Potential of KYV-101 for Treatment of Lupus Nephritis in Symposium at ACR Convergence 2024
Morgan Stanley Maintains Kyverna Therapeutics(KYTX.US) With Buy Rating, Maintains Target Price $40
Analysts Offer Insights on NA Companies: Kyverna Therapeutics, Inc. (KYTX), Mural Oncology Plc (MURA) and Copa Holdings (CPA)
Kyverna Therapeutics Advances in Cell Therapy Leadership
Kyverna Therapeutics | 10-Q: Q3 2024 Earnings Report
Kyverna Therapeutics | 8-K: Kyverna Therapeutics Provides Business Update and Reports Third Quarter 2024 Financial Results
Kyverna Therapeutics Reports Q3 EPS (80c), Consensus (79c)
Kyverna Therapeutics: James Chung, Chief Medical Officer, Will Step Dn From His Position Effective Nov 22 >KYTX
Kyverna Therapeutics 3Q Loss/Shr 80c >KYTX